Forma Therapeutics Is A Clinical Stage Biopharmaceutical Company Based In Watertownmassachusettsand Operates As A Subsidiary Of Novo Nordiskfounded In 2008 By Notable Biotech Leadersthe Company Focuses On Developing Innovative Therapeutics For Rare Hematologic Diseases And Cancersforma Is Dedicated To Improving Patient Outcomes Through Researchdevelopmentand Commercialization Of First In Class And Best In Class Treatments The Company Targets Conditions Such As Sickle Cell Disease And Various Cancersincluding Metastatic Castration Resistant Prostate Cancer And Acute Myeloid Leukemiaits Pipeline Features Clinical Stage Candidates Like Etavopivata Pyruvate Kinase R Activator For Sickle Cell Diseaseand Ft 7051A Cbp P300 Inhibitor For Prostate Cancerforma Utilizes A Proprietary Chemistry Platform For Molecule Discoveryenhancing Its Capabilities In Drug Developmentunder The Leadership Of Ceo Frank Leethe Company Promotes A Culture Of Diversitycollaborationand Patient Advocacyengaging Directly With Patient Communities To Strengthen Its Therapeutic Solutions
